Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination against group B streptococcus.

Paul T Heath1, Robert G Feldman

  • 1Department of Child Health and Vaccine Institute, St George's Hospital Medical School, London, UK. pheath@sghms.ac.uk.

Expert Review of Vaccines
|May 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal Group B <i>Streptococcus</i> Vaccination: A Three-Country European Consortium to Improve Surveillance and Data Readiness.

Clinical epidemiology·2026
Same author

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Current knowledge and future perspectives on management and prevention of group B streptococcus in neonates and young infants.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Preterm infants: immunity and immunisation.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Methodological framework for the surveillance of healthcare-associated infections in high-risk infants: the NeoIPC surveillance core module protocol.

Antimicrobial resistance and infection control·2026
Same author

Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Developing a Streptococcus agalactiae (Group B Streptococcus) vaccine is crucial for preventing infant disease and stillbirths. However, regulatory and legal hurdles, not scientific challenges, impede its market entry.

Area of Science:

  • Bacteriology
  • Vaccinology
  • Public Health

Background:

  • Streptococcus agalactiae (Group B Streptococcus) causes significant disease in infants, pregnant women, the elderly, and immunocompromised adults.
  • An effective Group B Streptococcus vaccine could prevent most infant infections, stillbirths, and prematurity, offering an alternative to intrapartum antibiotic prophylaxis.

Purpose of the Study:

  • To review the potential of various Streptococcus agalactiae vaccine candidates.
  • To identify the primary limitations hindering the development and market approval of a Group B Streptococcus vaccine.

Main Methods:

  • Review of existing scientific literature and clinical trial data for Streptococcus agalactiae vaccine candidates.
  • Analysis of the regulatory and legal landscape impacting vaccine development.

Related Experiment Videos

Main Results:

  • Several vaccine candidates show promise, including capsular conjugate vaccines (using tetanus toxoid or CRM197) and protein-based vaccines.
  • Capsular conjugate vaccines are the most advanced, with some completing Phase II trials in pregnant women.
  • The primary obstacles to a Group B Streptococcus vaccine are regulatory and legal, not scientific or technical.

Conclusions:

  • While scientific and technical challenges are surmountable, regulatory and legal barriers are the main impediments to a Group B Streptococcus vaccine.
  • Without changes in the regulatory environment, a Group B Streptococcus vaccine is unlikely to reach the market.
  • Vaccination in the third trimester of pregnancy is considered optimal for protecting infants.